Valeant to buy Bausch & Lomb for $8.7 billion


Valeant Pharmaceuticals International Inc said on Monday that it had inked an $8.7 billion cash deal to take over eye health company Bausch & Lomb Holdings.

The deal, to be financed through debt and equity, will see some $4.5 billion go to an investor group led by Warburg Pincus LLC, with some $4.2 billion used to pay down Bausch & Lomb's outstanding debt.

Continue Reading Below

(Reporting by Julie Gordon)